芪蓝胶囊抑制前列腺癌血管生成拟态相关蛋白表达的研究

Inhibitory effect of Qilan Capsules on the expressions of vasculogenic mimicry-related proteins in prostate cancer

目的:探讨芪蓝胶囊对前列腺癌血管生成拟态(VM)形成中缺氧诱导因子1α(HIF-1α)、血管内皮生长因子α(VEGFα)、上皮细胞激酶-2(EphA2)蛋白表达的抑制作用。方法:选用PC-3细胞,培养后进行si RNA转染,将细胞分为空白对照组、HIF-lαsi RNA组、VEGF-αsi RNA组、EphA2 si RNA组、芪蓝胶囊(中剂量)组、芪蓝胶囊+HIF-lαsi RNA组、芪蓝胶囊+VEGF-αsi RNA组、芪蓝胶囊+EphA2 si RNA组。采用Western印迹技术检测VEGF通路上各点的蛋白表达情况。结果:HIF-1α蛋白表达量结果中HIF-lαsi RNA组为0.032 8±0.002 5,芪蓝胶囊+HIF-lαsi RNA组为0.03 68±0.018 1,与空白组(0.624 7±0.042 8)相比,具有统计学意义(P<0.05)。VEGF-α蛋白表达量结果中VEGF-αsi RNA组为0.016 9±0.000 7,芪蓝胶囊+VEGF-αsi RNA组为0.010 9±0.000 8,与空白组(0.068 9±0.005 1)相比,具有统计学意义(P<0.05)。EphA2蛋白表达量结果中EphA2si RNA组为0.134 5±0.028 6,芪蓝胶囊+EphA2 si RNA组为0.165 4±0.039 8,与空白组(0.1684±0.0126)相比,差异无统计学意义(P>0.05)。MMP-1蛋白表达量结果示HIF-lαsi RNA、VEGF-αsi RNA、EphA2 si RNA组与空白组相比,均具有统计学差异(P<0.05)。结论:芪蓝胶囊通过抑制HIF-1α、VEGF-α、MMP-1蛋白的表达,从而使前列腺癌组织中VM形成受到抑制,影响了肿瘤组织自身血液供应系统的生长、发展过程,最终起到治疗前列腺癌的临床作用。

Objective： To investigate the effect of Qilan Capsules （QLC） on the expressions of the related proteins HIF-1α, VEGF-α, EphA2 and MMP-1 in the formation of vasculogenic mimicry （VM） in prostate cancer. Methods ： Prostate cancer PC-3 cells were cultured, transfected with siRNA, and divided into eight groups, blank control, HIF-lct siRNA, VEGF-αsiRNA, EphA2siRNA, QLC intervention, QLC ＋ HIF-1α siRNA, QLC ＋ VEGF-α siRNA, and QLC ＋ EphA2 siRNA. The expressions of the HIF-1 α, VEGF-α and EphA2 proteins in the pathway of VEGF were determined by Western blot. Results ： Compared with the blank control group, the expression of HIF-1α was evidently decreased in the HIF-1α siRNA and QLC ＋ HIF-1α siRNA groups （0.624 7 ± 0.042 8 vs 0.032 8 ＋ 0.002 5 and 0.036 8 ± 0.018 1, P 〈 0.05） , so were that of VEGF-α in the VEGF-α siRNA and QLC ＋ VEGF-α siRNA groups （0.068 9 ±0.005 1 vs 0.016 9 ±0.000 7 and 0.010 9 ± 0.000 8, P 〈 0.05）, that of EphA2 in the EphA2 siRNA and QLC ＋ EphA2 siRNA groups though with no statistically significant difference （0. 1684 ± O. 0126 vs O. 134 5 ± 0.028 6 and 0. 165 4 ± 0.039 8, P 〉 0.05）, and that of MMP-1 in the HIF-1α siRNA, VEGF-α siRNA and EphA2 siRNA groups （1.696 1 ± 0.1527vs0.4359± 0.0369, 0.1987 ± 0. 009 0 and 0. 0218 ± 0.0007, P 〈 0.05）. Conclusion： QilanCap- sules can suppress VM formation in prostate cancer by inhibiting the expressions of HIF-1α, VEGF-α and MMP-1, which plays a role in the clinical treatment of prostate cancer by checking the growth and development of the blood supply system in the tumor tissue.